bortezomib biotech 3,5 mg
venus pharma gmbh - germania - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice inhibitori de proteazom
abiraterona dr. reddy's 500 mg
synthon hispania, s.l. - spania - abirateronum - compr. film. - 500mg - antagonisti hormonali si substante inrudite alti antagonisti hormonali si substante inrudite
lenalidomida alkaloid-int 10 mg
synthon hispania s.l. - spania - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare
lenalidomida alkaloid-int 15 mg
synthon hispania s.l. - spania - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare
lenalidomida alkaloid-int 25 mg
synthon hispania s.l. - spania - lenalidomidum - caps. - 25mg - imunosupresoare alte imunosupresoare
lenalidomida alkaloid-int 5 mg
synthon hispania s.l. - spania - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare
bortezomib pharmidea 3,5 mg pulbere pentru soluţie injectabilă
sia pharmidea - bortezomibum - pulbere pentru soluţie injectabilă - 3,5 mg
thalidomide lipomed
lipomed gmbh - thalidomide - mielom multiplu - imunosupresoare - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.
bortezomib sandoz 3,5 mg
sandoz s.r.l. - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice alte antineoplazice
adcetris
takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - agenți antineoplazici - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.